Komipharm International Co., Ltd

As of March 31, 2026, Komipharm International Co., Ltd carries a market capitalization of 606.67B, placing it among publicly traded companies globally. Its enterprise value stands at 624.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Komipharm International Co., Ltd has 71.88M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 12.05, and the price-to-book ratio stands at 8.57.

As of March 31, 2026, Komipharm International Co., Ltd trades at an EV/EBITDA multiple of 140.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 12.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 356.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 624.86B versus a market cap of 606.67B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Komipharm International Co., Ltd maintains a current ratio of 1.31, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.85, indicating elevated leverage, while an interest coverage ratio of 1.94 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Komipharm International Co., Ltd posted a negative return on equity (ROE) of -9.61, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.98, reflecting losses generated across the asset base. The company generates approximately 298.47M in revenue per employee across its workforce of 167.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.17 indicates how many times Komipharm International Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Komipharm International Co., Ltd's stock has gained approximately 38.81% over the past 52 weeks. The 50-day moving average sits at 9,710.80, while the 200-day moving average is 8,484.20.

Over the twelve months ended March 31, 2026, Komipharm International Co., Ltd generated 49.99B in revenue and converted that into -6.40B in net income, yielding earnings per share of -101.01. EBITDA reached 4.45B, while operating income came in at 1.75B.

As of March 31, 2026, Komipharm International Co., Ltd holds 24.54B in cash and equivalents against 40.22B in total debt, resulting in a net debt position of 21.04B. Total book value stands at 70.81B, with working capital of 15.98B providing operational flexibility.

Komipharm International Co., Ltd produced -1.22B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -5.20B in capital expenditures, free cash flow totaled -6.43B - equivalent to -89.98 per share.

Over the twelve months ended March 31, 2026, Komipharm International Co., Ltd posted a gross margin of 33.83, reflecting its pricing power and cost economics. The operating margin of 3.50 and net profit margin of -12.80 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.49, meaning Komipharm International Co., Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Komipharm International Co., Ltd's most recent stock split took place on August 17, 2023 with a 725:798 split ratio.

As of March 31, 2026, Komipharm International Co., Ltd has an Altman Z-Score of 6.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.